Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study

BACKGROUND: This pilot study included 68 cases with post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups; intervention group (32 patients) received standard cough therapy, and montelukast 10 mg/day for 14 days and control group (36 patients) received only cough sedatives...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed Hussein, Aliae A. R., Ibrahim, Mohamed Eltaher A. A., Makhlouf, Hoda A., Makhlouf, Nahed A., Abd-Elaal, Howaida K., Kholief, Karima M. S., Sayed, Islam G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476462/
http://dx.doi.org/10.1186/s43168-022-00154-6
Descripción
Sumario:BACKGROUND: This pilot study included 68 cases with post-COVID-19 persistent cough (> 8 weeks), randomly allocated into two groups; intervention group (32 patients) received standard cough therapy, and montelukast 10 mg/day for 14 days and control group (36 patients) received only cough sedatives. RESULTS: We found a significant improvement in the number of cough paroxysms/day, cough severity visual analog scale, cough severity index and cough quality of life, shorter duration improvement, and minimal side effects in the interventional group. CONCLUSIONS: We suggest that montelukast may be effective to reduce the duration and severity of the persistent post-COVID-19 cough and further improve quality of life.

Ejemplares similares